Piramal Pharma Schedules Analyst and Institutional Investor Meetings from 28 May to 12 June 2026

Piramal Pharma Limited has informed stock exchanges of its upcoming schedule of analyst and institutional investor meetings, filed pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The intimation, dated 19th May, 2026, and signed by Company Secretary & Compliance Officer Maneesh Sharma, outlines five group or one-on-one investor conference engagements to be held across Mumbai between 28 May 2026 and 12 June 2026.

Scheduled Investor Meetings

The company is set to participate in a series of prominent investor conferences over the coming weeks. All meetings are structured as group or one-on-one interactions within investor conference formats, and all venues are located in Mumbai. The full schedule is detailed below:

Meeting Date:	Conference Name:	Nature of Meeting:	Venue:
28th May, 2026	360 ONE Capital (B&K) 16th Annual Investor Conference - Trinity India 2026	Group / One-on-one Meeting (Investor Conference)	Mumbai
2nd June, 2026	Bank of America's flagship India Conference	Group / One-on-one Meeting (Investor Conference)	Mumbai
4th June, 2026	Citi India Conference 2026	Group / One-on-one Meeting (Investor Conference)	Mumbai
8th June, 2026	ICICI Securities India Investor Conference 2026	Group / One-on-one Meeting (Investor Conference)	Mumbai
12th June, 2026	Goldman Sachs 2nd Annual India CRO/CDMO Tour	Group / One-on-one Meeting (Investor Conference)	Mumbai

Regulatory Disclosure

The intimation has been made in compliance with Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, which mandates listed companies to disclose schedules of analyst or institutional investor meetings to the stock exchanges. Piramal Pharma has noted that the dates mentioned are subject to change and that modifications may occur due to exigencies on the part of investors or the company.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-1.06%	-5.93%	+16.38%	-9.84%	-15.67%	-6.64%

Piramal Pharma has successfully passed a US Food and Drug Administration (FDA) inspection at its Digwal, Telangana facility and has received the Establishment Inspection Report (EIR), marking a significant regulatory milestone for the company.

US FDA Inspection Clearance at Digwal, Telangana

The receipt of the EIR from the US FDA signifies the formal closure of the inspection conducted at Piramal Pharma's Digwal manufacturing facility located in Telangana. The Establishment Inspection Report is issued by the US FDA upon the satisfactory conclusion of a facility inspection, and its receipt is considered an important indicator of compliance with regulatory standards.

Parameter:	Details
Regulatory Body:	US Food and Drug Administration (US FDA)
Facility:	Digwal, Telangana
Development:	Passed Inspection & Received Establishment Inspection Report (EIR)

Significance of the Development

The successful clearance of the US FDA inspection at the Digwal, Telangana facility underscores Piramal Pharma's adherence to manufacturing and quality standards as required by one of the world's most stringent pharmaceutical regulatory authorities. The EIR receipt represents the conclusion of the regulatory review process for this facility, reinforcing the site's compliance standing with the US FDA.